Purpose: Antipsychotic-prescribing patterns remain unclear in Asia. The aims of our study were to investigate prescribing trends of antipsychotic medication in the general population, children, and older patients by drug generation (first or second), the prescribing trend in pregnant women, the probable indication for antipsychotic prescription, and the prescribing trend by dosage form. Results: The study included 10 109 206 prescriptions of any antipsychotics to 256 903 patients. Over the study period, the prevalence of antipsychotic prescribing increased from 1.06% to 1.54% in the general population, from 0.10% to 0.23% in children (3-17 years old), and from 2.61% to 3.26% in older patients (≥65 years old). The prevalence of second-generation antipsychotics increased, but the prevalence of first-generation antipsychotics did not. Prevalence of antipsychotic prescribing in prepregnancy, pregnancy, and postpartum timeframes varied from 0.18% to 0.38%. The percentage of incident prescriptions with a diagnosis of psychosis decreased from 54.1% to 47.5%.
| INTRODUCTION
Antipsychotic drugs (APDs) have been commonly prescribed for the management of schizophrenia, bipolar disorder, and major depressive disorder. 1 Safety concerns about APDs use in specific patient groups including older patients, children, and pregnant women have been raised in past decades. Increased risk of mortality with the use of first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) in older patients with dementia has been reported. [2] [3] [4] [5] [6] Second-generation antipsychotics were approved for some indications in children and adolescents recently. 7 However, concerns regarding the safety of SGAs use in children (mostly focusing on metabolic syndrome and cardiovascular effects) have been raised. 8, 9 Although APDs have been increasingly prescribed during pregnancy, safety evidence is limited. 10, 11 The prescribing prevalence of APDs in general practice (GP) settings in the United Kingdom (UK) and Italy have been reported as 1% to 1.6% between 2000 and 2011. [12] [13] [14] [15] [16] In Asia, APD prescribing was only investigated in patients with psychotic disorders through a survey, [15] [16] [17] and their use in the general population of patients and in vulnerable patient groups (children, older patients, and pregnant women) remains unclear.
Concerns with respect to off-label use of APDs have also been reported. Antipsychotic drugs, especially SGAs, have been widely used off label for the management of mental disorders including but not limited to anxiety, attention deficit hyperactivity disorder, dementia, and severe agitation in older adults. 18, 19 From 2007 to 2011 in UK primary care settings, over half of patients prescribed with FGAs had diagnoses of nonpsychotic mental disorders, and a similar proportion was reported in patients receiving SGAs. 13 Information regarding off-label use of APDs has not been studied in Asia.
In addition, although there is limited evidence suggesting superior efficacy and safety of APDs depot injections compared to oral dosage, 20 depot injections were prescribed for one quarter to one third of patients with schizophrenia in western countries. 21 However, we could find no previous published studies of the use of APDs in depot injections or other dosage forms in an Asian population.
There were 4 specific objectives of our study to investigate prescribing of APDs in Hong Kong (HK), namely, to determine the following:
1. The prescribing trend over time of APDs in the general patient population, children, and older patients by drug generation (FGAs/SGAs).
2. The prescribing trend over time of APDs in prepregnancy, pregnancy, and postpartum timeframes. (Table S1 ). Antipsychotic drug prescriptions were further categorized according to dosage form (Table S2 ).
| Study population
We retrieved all prescription records of APDs from CDARS. Age was defined using mid-year age, which is age on 1st of July in the year of date of prescription, and used to group individuals as children (3-17 years old) and older patients (≥65 years old). 
| Prevalence in pregnancy
We identified pregnant women with records of delivery episodes from 
| Indication analysis
Using the ICD-9-CM, mental illnesses were categorized as organic psychotic conditions (290-294); other psychoses (295-299); neurotic disorders, personality disorders, and other nonpsychotic mental disorders (300-316); and intellectual disabilities (317-319). Since diagnosis records of chronic mental disorders are more likely to be omitted in nonincident prescriptions, this analysis only included new users of APDs.
As indication information is not available in CDARS, all mental illnesses diagnosed within 180 days before or after incident prescriptions (the first prescription during the study period) were retrieved and considered as 
| Statistical analysis
This descriptive study calculated prevalence (%) using the number of patients in the respective category divided by the total general (Table 1) . Haloperidol (20.7%), chlorpromazine (9.5%), and sulpiride (7.6%) were the most frequently prescribed FGAs in HK over this period, while risperidone (12.1%), quetiapine (11.3%), and clozapine (7.1%) were the 3 most commonly prescribed SGAs (Table S1 ).
The prevalence of APD prescribing in the general population increased 45% from 1.06% (2004) Table S4 ).
In older patients, the prevalence of APD prescribing increased 24% (Table S2 ).
The highest statistical power of the trend tests for oral solution, immediate injection, and depot injection prescribing prevalence was .48.
| DISCUSSION
Antipsychotic drug prescribing is increasing in HK in the general population, children, and older patients. The prevalent usage and increase are particularly notable in older patients. Although an increase in SGA prescribing was found, SGA prescribing was less prevalent in HK compared to western countries. During the study period, the percentage of incident prescriptions for organic psychotic conditions increased, as did the prescriptions for nonpsychotic disorders. Finally, the most commonly prescribed dosage form, which was oral tablets/ capsules, increased over the study period, while the prevalence of depot injections remained stable.
| Interpretation and comparison with other studies
We found that 1.06% (2004) shows a similar increase in APD prescribing to the data in our study, which provides a comprehensive view of drug prescribing from outpatient, inpatient, and emergency departments. However, comparison between our results and data from other sources needs to take full account of the differences of data source in the groups studied.
Differences in APD prescribing were found in specific age groups, including children and older patients, when comparing the results of our study to those from other regions. Results of a survey study con- Compared to HK, SGAs were generally more frequently prescribed in other regions. Our study showed that the SGA prevalence did not increased prevalence, as suggested in a previous study. 42 Other reasons could be an increase in the approved indications of SGAs, which are now approved for the treatment of bipolar mania, adolescent schizophrenia, and behavioural disturbance associated with autism or intellectual disability in children and adolescents. 7 With regard to APD prescribing in pregnancy, it was expected that the prevalence would take the "U-shape" pattern (statistically significantly higher prevalence in the timeframes of prepregnancy and postpartum, compared to the pregnancy timeframe). 43 However, this was not the case in our study. Although no statistically significant change was detected, our study indicates that APD prescribing remains common during the prepregnancy, pregnancy, and postpartum timeframes. 44 As shown in our results, no statistically significant change was detected in the annual prevalence of APD depot injection prescribing.
| Strength of this study
To our knowledge, this is the first study describing APD-prescribing trends using population-based database in Asia. Apart from providing information on APD prescribing in the general patient population and patient groups of interest, this study also provides prescribing data by dosage form and on the probable indication of incident APD prescriptions. Although there are publications on surveys/audits of APD prescribing/use conducted in Asia at local hospitals or certain regional clinics, we could find no previous publications on population-based data. In contrast, data used in this study were derived from CDARS, which consists of medical records from the HK public healthcare sectors, including inpatient, outpatient, and emergency department prescriptions.
| Limitations of this study
Since the database used in this study was derived from the public healthcare system, antipsychotic prescriptions in private clinics were not included, implying that the prevalence of APDs prescribing may have been underestimated. A previous study suggested that public healthcare institutions were the mainstay of the mental health service in HK. 45 As APDs are generally chronic treatment and patients who require long-term follow-up are more likely to use public healthcare because of the lower costs, the CDARS data in this study are likely to have captured most of the APDs prescriptions in HK. In cases where the change in trend over time was not statistically significant, the analyses were underpowered. Results of this study might not be generalizable to healthcare systems of other countries/regions due to different local practice of patient care and age distribution in study population. Other psychoses (ICD-9-CM 295-299). Nonpsychotic mental disorder (ICD-9-CM 300-316). Intellectual disabilities (ICD-9-CM 317-319). Organic psychoses conditions (ICD-9-CM 290-294).
| CONCLUSION
Our study has confirmed an increasing trend in APD prescribing to older patients, suggesting that attention should particularly focus on the safety and tolerability profile of APDs in this age group. Further evidence to support the effectiveness and safety of off-label use of APDs is required. With the changes in APD prescribing over time, it is important to determine not only the differences in beneficial effects but also differences in adverse effects, particularly for serious, rare, and delayed adverse effects, which may only emerge after considerable clinical experience has been accumulated. Future observational studies using population-based data could be of great value in this regard.
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